Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Unmet needs in diagnosis and management of portopulmonary hypertension: How far have we reached?
Krowka, Michael J. , Raevens, Sarah , Fallon, Michael B. , DuBrock, Hilary M.

Mayo Clinic

Hepatology | December 26, 2024 | Volume: 84 | Issue: 2 | Pages: 573-581

10.1097/hep.0000000000001218 | PMID 39723999 Get It

Portopulmonary hypertension (POPH), a form of pulmonary artery hypertension, occurs because of portal hypertension. Pulmonary hemodynamics and right heart function are key entities that are considered when diagnosing and treating POPH. Medical management, combined with liver transplantation, offers a unique opportunity for POPH “cure”; however, transplant risk can be significant as it relates to the severity of POPH. In addition to recent POPH practice guidelines, continued efforts can be suggested to improve our understanding of prognostic factors, investigate newer medical treatments, and improve outcomes of POPH. Herein, we identify specific “unmet needs” that focus on expanding and complementing current POPH practice guidelines.
Distinctive clinical features in biopsy-proven nerve large-arteriole vasculitis and microvasculitis
Soontrapa, Pannathat , Pinto, Marcus Vinícius , Shouman, Kamal , Mandrekar, Jay , Engelstad, JaNean , Pinto, Catarina Aragon , Taylor, Sean , Mauermann, Michelle L. , Berini, Sarah E. , Bosch, E. Peter, Rubin, Devon I., Weyand, Cornelia M. , Dyck, Peter James , Pinto, Marcus V , Mauermann, Michelle L , Soontrapa, Pannathat , Koster, Matthew J. , Warrington, Kenneth J. , Klein, Christopher J.

Mayo Clinic

Brain | December 20, 2024 | Volume: 148 | Issue: 3 | Pages: 1031-1042

10.1093/brain/awae406 | PMID 39715342 Get It

Abstract Vasculitic neuropathy is caused by inflammatory destruction of nerve blood vessels resulting in nerve ischaemia. Nerve vasculitis can be divided into two categories based on vessel size: large-arteriole vasculitis (≥75 µm) and microvasculitis (<75 µm). Herein, we characterize the clinical features of nerve large-arteriole vasculitis in comparison to nerve microvasculitis. This is a retrospective cohort study of patients evaluated and biopsied at Mayo sites between 2001 and 2020. We collected clinical and histopathological data from patients whose nerve biopsies were either diagnostic or highly suggestive of nerve vasculitis. Two hundred and seventy-eight cases were identified: 125 cases of large-arteriole vasculitis and 153 cases of microvasculitis. Nerve large-arteriole vasculitis presented with a more acute (50.4% versus 26.8%) versus chronic onset (33.6% versus 57.5%) than nerve microvasculitis (P = 0.0001). Nerve microvasculitis had longer mean time to diagnosis (10.5 versus 4.3 months; P < 0.0001) and longer time to plateau (8.9 versus 3.5 months; P < 0.0001). Nerve large-arteriole vasculitis typically presented as distal asymmetric polyneuropathy (48.0%), whereas nerve microvasculitis typically presented as radiculoplexus neuropathy/polyradiculoneuropathy (more proximal involvement of shoulder and thigh) (43.8%) (P < 0.0001). Systemic autoimmune disease was more common in nerve large-arteriole vasculitis (70.4% versus 22.9%, odds ratio, 8.0; 95% confidence interval, 4.7–13.7; P < 0.0001). Nerve microvasculitis was significantly related to non-systemic vasculitis (71% versus 23%, odds ratio, 7.9; 95% confidence interval, 4.6–13.6; P < 0.0001). Nerve microvasculitis had more autonomic involvement (24.2% versus 7.2%, odds ratio, 4.1; 95% confidence interval, 1.9–8.9; P = 0.0002). Nerve large-arteriole vasculitis and nerve microvasculitis have different but overlapping clinical features. Nerve large-arteriole vasculitis usually presents with acute onset, distal asymmetric polyneuropathy, associated with other autoimmune diseases and systemic involvement. In contrast, nerve microvasculitis usually presents with a subacute/chronic onset, as radiculoplexus neuropathy/polyradiculopathy (distal and proximal pattern) with autonomic involvement, and is more often a form of non-systemic vasculitis.
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Shore, Neal D. , Nielsen, Sarah M. , Esplin, Edward D. , Antonarakis, Emmanuel S. , Barata, Pedro C. , Beltran, Himisha , Bryce, Alan H. , Cookson, Michael S. , Crawford, E. David , Dorff, Tanya B. , George, Daniel J. , Heath, Elisabeth I. , Hussain, Maha , McKay, Rana R. , Ross, Ashley E. , Shen, John , Sieber, Paul , Armstrong, Andrew J. , Antonarakis, Emmanuel S. , Shore, Neal , Beer, Tomasz M , Beltran, Himisha , Bryce, Alan H , Dorff, Tanya , George, Daniel J , Heath, Elisabeth I , Helfand, Brian T. , Hussain, Maha H A , McKay, Rana R , Morgans, Alicia K , Morris, Michael J , Ross, Ashley E , Sartor, A Oliver , Wise, David R , Armstrong, Andrew J , Barata, Pedro , Antonarakis, Emmanuel S , Esplin, Edward D , Antonarakis, Emmanuel S , Beer, Tomasz M. , Morgans, Alicia K. , Morris, Michael J. , Paller, Channing J. , Sartor, Oliver , Smith, Matthew Ryan

Mayo Clinic

JCO Oncology Practice | December 19, 2024 | Volume: 21 | Issue: 6 | Pages: 747-753

10.1200/op-24-00626 | PMID 39700441 Get It

Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.
Socioeconomic Inequities in Preemptive Kidney Transplantation and Graft Survival: An Innovative Approach to Identifying Disparities in Kidney Transplantation
Kizilbash, Sarah J. , Roy, Madison, Ryu, Euijung , Matas, Arthur J., Juhn, Young J. , Garovic, Vesna, Juhn, Young, Kizilbash, Sarah , Wi, Chung‐Il , Garovic, Vesna D. , Riad, Samy , Schinstock, Carrie A.

Mayo Clinic

Transplantation Direct | December 19, 2024 | Volume: 11 | Issue: 1 | Pages: e1734

10.1097/txd.0000000000001734 | PMID 39703725 Get It

Background. The limitations of conventional measures of socioeconomic status (SES) limit our ability to elucidate the role of SES as a key element of social determinants of health in kidney transplantation. This study’s objective was to use an innovative SES measure, the HOUsing-based SES measure (HOUSES) index, to examine the effects of social determinants of health on access to and outcomes of kidney transplantation. Methods. Our study included residents of Minnesota (age older than 18 y) who underwent kidney transplantation at a single center between 2010 and 2020. SES was determined using the HOUSES index, categorized into quartiles (Q1 for lower, Q2–Q4 for higher SES). We used mixed-effects multivariable logistic and Cox models to examine the effects of HOUSES on preemptive transplants, pretransplant dialysis duration, and death-censored graft loss, adjusting for covariates. Results. Among 1975 eligible patients, 29.4% received preemptive transplants, 34.9% underwent pretransplant dialysis for >3 y, and 15.1% experienced death-censored graft loss for a median follow-up of 7.15 (interquartile range, 4.25–11.38) y. Lower SES recipients (Q1) demonstrated decreased preemptive transplant likelihood (adjusted odds ratio [aOR]: 0.74; 95% confidence interval [CI], 0.57-0.97; P = 0.03), longer dialysis duration (>3 y; aOR: 1.43; 95% CI, 1.01-2.03; P = 0.046), and higher death-censored graft loss (adjusted hazard ratio 1.36; 95% CI, 1.02-1.12; P = 0.036) versus higher SES recipients (Q2–Q4). Conclusions. We observed significant socioeconomic disparities in kidney transplant access, dialysis duration, and graft survival. The HOUSES index may be a promising tool for individual-based targeted interventions as it identifies SES on an individual rather than an area-level basis.
Cumulative deficits frailty index and relationship status predict survival in multiple myeloma
Abdallah, Nadine , Dizona, Paul, LaPlant, Betsy, Schaeferle, Gavin, Aug, Sarah, Weivoda, Megan , Buadi, Francis K. , Warsame, Rahma , Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Menser, Terri , Weivoda, Megan , Dispenzieri, Angela , Buadi, Francis K , Warsame, Rahma , Cook, Joselle M , Lacy, Martha Q , Gertz, Morie A , Kumar, Shaji K , Kumar, Amanika , Dispenzieri, Angela , Cook, Joselle , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | December 18, 2024 | Volume: 9 | Issue: 5 | Pages: 1137-1146

10.1182/bloodadvances.2024014624 | PMID 39693516 Get It

Abstract Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most are based on clinical trial data sets. There are also limited data on the association between frailty and patient-reported outcomes and on the prognostic value of social determinants of health. This study evaluates the prognostic impact of frailty, based on the cumulative deficit frailty index (FI), and relationship and socioeconomic status (SES) in patients with newly diagnosed MM. This retrospective study included 515 patients with MM seen at Mayo Clinic (Rochester, MN) at diagnosis between 2005 and 2018. The FI was calculated using patient-reported data on activities of daily living and comorbidity data, with items scored as 0, 0.5, or 1, in which 1 indicated a deficit. The FI was calculated by dividing the total score by the number of nonmissing items. Frailty was defined as FI ≥0.15; 61% were nonfrail, and 39% were frail. Frailty and nonmarried/relationship status were associated with higher disease stage, decreased the likelihood of early transplantation, and independently associated with decreased survival. SES was not independently associated with survival. Frail patients reported worse scores for fatigue, pain, and quality of life. Approximately a quarter of patients had a deterioration in frailty status at 3 to 12 months, and <10% had improvement. In conclusion, a cumulative deficit FI was associated with higher symptom burden and decreased survival in a real-world cohort of patients with newly diagnosed MM. Frailty status is dynamic and should be reassessed during treatment. Social support has prognostic value and should be evaluated in clinical practice.
Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study
Ablon, Glynis , Bank, David, Kontis, Theda C., Ibrahim, Sherrif F., Palm, Melanie D., Cox, Sue Ellen , Grunebaum, Lisa D., Goldman, Mitchel P. , Humphrey, Shannon , Coquis-Knezek, Sarah, Grunebaum, Lisa, Rivers, Jason Keller

Mayo Clinic

Dermatologic Surgery | December 18, 2024 | Volume: 51 | Issue: 3 | Pages: 277-283

10.1097/dss.0000000000004470 | PMID 39692332 Get It

BACKGROUND RelabotulinumtoxinA (RelaBoNT-A) is a complex-free, ready-to-use, liquid botulinum toxin A. OBJECTIVE Efficacy/safety of RelaBoNT-A treatment for lateral canthal lines (LCL). METHODS Randomized adults received RelaBoNT-A (30 U/side; n = 230) or placebo (n = 73) during a 6-month, double-blind, Ph3 study (Relabotulinumtoxin Aesthetic Development Study-2 [READY-2]). Primary end points (Month 1, maximum smile) comprised: composite ≥2-grade responder rate using concurrent LCL severity investigator live assessment (LCL-ILA) and subject live assessment (LCL-SLA); LCL-ILA 0 (none)/1 (mild) responder rate. Subject satisfaction and adverse events were also reported. RESULTS Month 1 composite ≥2-grade responder rates were 51.8% (RelaBoNT-A) and 1.4% (placebo; (p < .001). Month 1 none/mild LCL-ILA responder rates were 87.2% (RelaBoNT-A) and 11.9% (placebo; p < .001). Onset was reported Day 1 by 34%. At Month 6, LCL-ILA responder rates for RelaBoNT-A remained at 23.3% (none/mild) and 35.9% (≥1-grade improvement). Median return to baseline severity was 24.7 weeks; 64% (RelaBoNT-A group) had not returned to baseline at Month 6. RelaBoNT-A satisfaction was high through Month 6 (71%). Mild/moderate treatment-related adverse events occurred in 6.1% (RelaBoNT-A) and 5.5% (placebo). CONCLUSION RelaBoNT-A (60 U) treatment provided statistically significant improvement of moderate-to-severe LCL. One-third of subjects reported onset within 1 day and improvements were maintained through Month 6. Treatment satisfaction was high. RelaBoNT-A was well tolerated.
How I diagnose high-grade B-cell lymphoma
Moore, Erika M. , Gibson, Sarah E. , Gibson, Sarah E

Mayo Clinic

American Journal of Clinical Pathology | December 17, 2024 | Volume: 163 | Issue: 4 | Pages: 487-500

10.1093/ajcp/aqae158 | PMID 39689165 Get It

Abstract Objectives High-grade B-cell lymphoma (HGBL), introduced in the 2016 World Health Organization (WHO) revised fourth edition classification, included cases defined by MYC and BCL2 and/or BCL6 rearrangements or by high-grade morphology. Diagnostic criteria and nomenclature for these lymphomas were refined in the 2022 WHO fifth edition (WHO-5) classification and International Consensus Classification (ICC). This review describes our approach to the diagnosis of HGBL. Methods Two cases are presented illustrating how we diagnose HGBL, including 1 case harboring MYC and BCL6 rearrangements and a second showing TdT expression in an HGBL with MYC and BCL2 rearrangements. The ways in which these cases are distinguished from other lymphomas with high-grade features and the appropriate nomenclature using WHO-5 and ICC classifications are emphasized. Results An HGBL diagnosis requires integration of morphology, immunophenotype, and genetics and exclusion of other lymphomas with high-grade morphology, including Burkitt lymphoma, B-lymphoblastic leukemia/lymphoma (B-LBL/ALL), and blastoid mantle cell lymphoma. A diagnosis of HGBL/large B-cell lymphoma with 11q aberration should also be considered in certain patient populations. Conclusions High-grade B-cell lymphomas are subclassified based on morphologic and genetic features. There are differences in the nomenclature and definition of these lymphomas in the WHO-5 and ICC classifications. Distinguishing HGBLs from other mature B-cell lymphomas and B-LBL/ALL is critical so that patients receive appropriate treatment.
Impact of rapid antibiotic susceptibility testing for Gram-negative bacteremia varies by pathogen type and resistance: a secondary analysis of the RAPIDS GN trial
Banerjee, Ritu , Giri, Abhigya, Komarow, Lauren , Souli, Maria , Doernberg, Sarah B. , Patel, Robin , Group, on behalf of the Antibacterial Resistance Leadership, Banerjee, Ritu , Patel, Robin , Group, on behalf of the Antibacterial Resistance Leadership

Mayo Clinic

Microbiology Spectrum | December 16, 2024 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/spectrum.01789-24 | PMID 39679788 Get It

ABSTRACT In this secondary analysis of 386 subjects with Gram-negative bacteremia enrolled in the RAPIDS GN trial, rapid antibiotic susceptibility testing had a greater benefit on the management of bacteremia caused by antibiotic-resistant compared to antibiotic-susceptible isolates, especially for Escherichia coli, Klebsiella species , and Proteus species. IMPORTANCE Rapid blood culture diagnostics are costly, and their use has not demonstrated clear clinical benefit for patients with Gram-negative sepsis, possibly because prior trials did not enroll sufficient numbers of patients with antibiotic-resistant infections. This analysis of patients with sepsis previously enrolled in a randomized controlled clinical trial demonstrates that rapid susceptibility testing of bacteria from blood cultures had the greatest impact for patients with antibiotic-resistant infections. Specifically, after rapid testing results were reported, patients infected with resistant bacteria received appropriate antibiotic therapy more quickly than patients with susceptible bacteria. These findings highlight the need to evaluate blood culture diagnostics in areas with high antibiotic resistance where these diagnostics are likely to have the greatest impact.
Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk
Milne, Roger L. , John, Esther M. , Andrulis, Irene L., Colonna, Sarah V. , Phillips, Kelly‐Anne , Investigators, kConFab, Marchand, Loı̈c Le , Phipps, Amanda I. , Schmit, Stephanie L. , Gallinger, Steven , Pai, Rish K. , Samadder, N. Jewel , Thorne, Heather , Maclnnis, Robert , Jenkins, Mark A , Milne, Roger L , John, Esther M , Andrulis, Irene L , Colonna, Sarah V , Phillips, Kelly-Anne , Marchand, Loïc Le , Schmit, Stephanie L , Macrae, Finlay A , Buchanan, Daniel D , Gallinger, Steven , Pai, R K , Samadder, N Jewel , Giles, Graham G , Southey, Melissa C , Hopper, John L. , Terry, Mary Beth , MacInnis, Robert J. , Jenkins, Mark A. , Daly, Mary Beryl , Investigators, kConFab, Newcomb, Polly A. , Macrae, Finlay , Buchanan, Daniel D. , Giles, Graham G. , Southey, Melissa C. , Hopper, John L. , Terry, Mary Beth

Mayo Clinic

JNCI Cancer Spectrum | December 14, 2024 | Volume: 9 | Issue: 1 | Pages: No page available

10.1093/jncics/pkae121 | PMID 39673461 Get It

Abstract Menopausal users of hormone replacement therapy (HRT) are at increased breast cancer risk and decreased colorectal cancer (CRC) risk compared with individuals who have never used HRT, but these opposing associations may differ by familial risk of breast cancer and CRC. We harmonized data from 3 cohorts and generated separate breast cancer and CRC familial risk scores based on cancer family history. We defined moderate or strong family history as a risk score of 0.4 or higher, where 0.4 was equivalent to a 50-year-old woman with 1 parent diagnosed with either breast cancer or CRC at 55 years of age. Of 24 486 women assessed, 1243 and 405 were diagnosed with incident breast cancer and CRC, respectively. For breast cancer, menopausal HRT ever use versus never use hazard ratios were 1.27 (95% CI = 1.11 to 1.45) for a breast cancer familial risk score below 0.4 and 1.01 (95% CI = 0.82 to 1.25) for a breast cancer familial risk score of 0.4 or higher (Pdifference = .08). For CRC, menopausal HRT hazard ratios were 0.63 (95% CI = 0.50 to 0.78) for a CRC familial risk score below 0.4 and 1.21 (95% CI = 0.73 to 2.00) for a CRC familial risk score of 0.4 or higher (Pdifference = .03). Associations with menopausal HRT use that apply to the general population may not hold for women at moderate or strong familial risk of these cancers.
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff, Rachna T. , King, Gentry Teng , Colby, Sarah, Scott, Aaron J. , Borad, Mitesh J. , Goff, Laura W. , Matin, Khalid , Mahipal, Amit , Kalyan, Aparna, Javle, Milind , Dika, Imane El , Tan, Benjamin , Cheema, P. , Iyer, Renuka , Kelley, Robin Kate , Thumar, Jaykumar , Guthrie, Katherine A. , Chiorean, E. Gabriela , Höchster, Howard S. , King, Gentry , Javle, Milind M , Cheema, Puneet S , Patel, Anuj , Iyer, Renuka , Kelley, R Katie , Thumar, Jaykumar , El-Khouiery, Anthony B , Chiorean, E Gabriela , Hochster, Howard , Philip, Philip , Mahipal, Amit , Borad, Mitesh J , Patel, Anuj , El-Khoueiry, Anthony B. , Philip, Philip A.

Mayo Clinic

Journal of Clinical Oncology | December 13, 2024 | Volume: 43 | Issue: 5 | Pages: 536-544

10.1200/jco-24-01383 | PMID 39671534 Get It

PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METHODS Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m 2 , cisplatin 25 mg/m 2 , and nab-paclitaxel 100 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle). RESULTS Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC. There was no significant difference in overall survival (OS) between GAP versus GC. Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41. Median progression-free survival (PFS) was similar between groups with median PFS for GAP being 7.5 months (95% CI, 6.4 to 8.5) versus 6.3 months for GC (95% CI, 4.4 to 8.2); HR, 0.89 (95% CI, 0.71 to 1.12); P = .32. In exploratory subset analyses, the OS and PFS benefits of GAP versus GC treatment were greater in locally advanced disease compared with metastatic disease, although not statistically significant (interaction P = .14 for OS and P = .17 for PFS). Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28). CONCLUSION The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC. More toxicity was encountered with GAP versus GC.